CA2212237A1 - Novel antineoplastic agents - Google Patents

Novel antineoplastic agents

Info

Publication number: CA2212237A1
Authority: CA; Canada
Prior art keywords: hydrogen; aralkyl; cycloalkyl; aryl; compound
Prior art date: 1997-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002212237A

Other languages

English (en)

French (fr)

Inventor

John M. Webster

Jianxiong Li

Genhui Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

1997-09-05

Publication date

1999-03-05

1997-09-05 Application filed by Individual filed Critical Individual

1997-09-05 Priority to CA002212237A priority Critical patent/CA2212237A1/en

1998-09-03 Priority to EP98942414A priority patent/EP1009401A1/en

1998-09-03 Priority to CN98810328A priority patent/CN1276723A/zh

1998-09-03 Priority to PCT/CA1998/000841 priority patent/WO1999012543A1/en

1998-09-03 Priority to AU90570/98A priority patent/AU759990B2/en

1998-09-03 Priority to JP2000510440A priority patent/JP2001515861A/ja

1999-03-05 Publication of CA2212237A1 publication Critical patent/CA2212237A1/en

2001-09-06 Priority to CN01131401A priority patent/CN1360891A/zh

2002-11-02 Priority to HK02107990.3A priority patent/HK1046373A1/zh

Status Abandoned legal-status Critical Current

Links

239000002246 antineoplastic agent Substances 0.000 title description 25
229940034982 antineoplastic agent Drugs 0.000 title description 24
150000001875 compounds Chemical class 0.000 claims abstract description 36
206010028980 Neoplasm Diseases 0.000 claims abstract description 19
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
238000000034 method Methods 0.000 claims abstract description 18
150000003839 salts Chemical class 0.000 claims abstract description 16
230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 6
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
239000001257 hydrogen Substances 0.000 claims abstract 17
125000000217 alkyl group Chemical group 0.000 claims abstract 9
125000003710 aryl alkyl group Chemical group 0.000 claims abstract 9
125000003118 aryl group Chemical group 0.000 claims abstract 9
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 9
125000000623 heterocyclic group Chemical group 0.000 claims abstract 9
125000002252 acyl group Chemical group 0.000 claims abstract 7
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
201000010099 disease Diseases 0.000 claims description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
230000001613 neoplastic effect Effects 0.000 claims description 5
150000002431 hydrogen Chemical group 0.000 claims 12
238000010790 dilution Methods 0.000 claims 6
239000012895 dilution Substances 0.000 claims 6
239000003937 drug carrier Substances 0.000 claims 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
230000002401 inhibitory effect Effects 0.000 claims 3
241001465754 Metazoa Species 0.000 abstract description 6
241000123579 Xenorhabdus bovienii Species 0.000 abstract description 4
239000003814 drug Substances 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
MHMRAFONCSQAIA-UHFFFAOYSA-N thiolutin Chemical compound S1SC=C2N(C)C(=O)C(NC(=O)C)=C21 MHMRAFONCSQAIA-UHFFFAOYSA-N 0.000 description 21
210000004027 cell Anatomy 0.000 description 20
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
239000000203 mixture Substances 0.000 description 17
201000011510 cancer Diseases 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
230000000975 bioactive effect Effects 0.000 description 12
KDDABMWLWNRHGO-UHFFFAOYSA-N dithiolo[4,3-b]pyrrole 1-oxide Chemical class N1=CC=C2S(=O)SC=C21 KDDABMWLWNRHGO-UHFFFAOYSA-N 0.000 description 10
239000000126 substance Substances 0.000 description 10
LJRHSDGQWGPCCR-UHFFFAOYSA-N thiolutin Natural products S1SC=C2NC(=O)C(NC(=O)C)C21 LJRHSDGQWGPCCR-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
238000002451 electron ionisation mass spectrometry Methods 0.000 description 8
230000001093 anti-cancer Effects 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
238000000855 fermentation Methods 0.000 description 6
230000004151 fermentation Effects 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
ZHGZIFCTZVOLMX-UHFFFAOYSA-N 5-methyl-n-(5-oxo-4h-dithiolo[4,3-b]pyrrol-6-yl)hexanamide Chemical compound S1SC=C2NC(=O)C(NC(=O)CCCC(C)C)=C21 ZHGZIFCTZVOLMX-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000244206 Nematoda Species 0.000 description 4
239000003480 eluent Substances 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
ZXLPBBAXZZCKNU-UHFFFAOYSA-N n-(4-methyl-5-oxodithiolo[4,3-b]pyrrol-6-yl)hexanamide Chemical compound S1SC=C2N(C)C(=O)C(NC(=O)CCCCC)=C21 ZXLPBBAXZZCKNU-UHFFFAOYSA-N 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
241000607757 Xenorhabdus Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000008272 agar Substances 0.000 description 3
UGZYFXMSMFMTSM-UHFFFAOYSA-N aureothricin Chemical compound S1SC=C2N(C)C(=O)C(NC(=O)CC)=C21 UGZYFXMSMFMTSM-UHFFFAOYSA-N 0.000 description 3
WAYBAXDAQZLSTG-UHFFFAOYSA-N aureothricin Natural products CCC(=O)NC1C2SSC=C2NC1=O WAYBAXDAQZLSTG-UHFFFAOYSA-N 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
HBUNPJGMNVQSBX-UHFFFAOYSA-N holomycin Chemical compound S1SC=C2NC(=O)C(NC(=O)C)=C21 HBUNPJGMNVQSBX-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000011160 research Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
241000255896 Galleria mellonella Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
239000012425 OXONE® Substances 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
244000309464 bull Species 0.000 description 2
231100000357 carcinogen Toxicity 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
201000007455 central nervous system cancer Diseases 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
229960000367 inositol Drugs 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 2
235000015497 potassium bicarbonate Nutrition 0.000 description 2
229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
239000011736 potassium bicarbonate Substances 0.000 description 2
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000000523 sample Substances 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
CDVZCUKHEYPEQS-CYUSJSHGSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanal;(2r,3s,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-CYUSJSHGSA-N 0.000 description 1
LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 1
ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 description 1
PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
238000005684 Liebig rearrangement reaction Methods 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
229910004809 Na2 SO4 Inorganic materials 0.000 description 1
DLLGWRDDCZZZFR-NPTBXDQBSA-N OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLLGWRDDCZZZFR-NPTBXDQBSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
241001148062 Photorhabdus Species 0.000 description 1
241001646398 Pseudomonas chlororaphis Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
241000718044 Streptomyces luteosporeus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
150000008043 acidic salts Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003905 agrochemical Substances 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
239000012681 biocontrol agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
150000001793 charged compounds Chemical group 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000000967 entomopathogenic effect Effects 0.000 description 1
XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013100 final test Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229960002160 maltose Drugs 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
244000005700 microbiome Species 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
JIEMCPGFAXNCQW-XVYZEKPJSA-N thiomarinol A Chemical compound O[C@@H]1[C@H](O)[C@@H](C/C=C/[C@@H](C)[C@@H](O)C)CO[C@H]1[C@H](O)C(\C)=C\C(=O)OCCCCCCCC(=O)NC(C(N1)=O)=C2C1=CSS2 JIEMCPGFAXNCQW-XVYZEKPJSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000001974 tryptic soy broth Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA002212237A 1997-09-05 1997-09-05 Novel antineoplastic agents Abandoned CA2212237A1 (en)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
CA002212237A CA2212237A1 (en)	1997-09-05	1997-09-05	Novel antineoplastic agents
EP98942414A EP1009401A1 (en)	1997-09-05	1998-09-03	Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agents
CN98810328A CN1276723A (zh)	1997-09-05	1998-09-03	用作抗肿瘤剂的二硫杂环戊烯并吡咯酮及其相应的一氧化物和二氧化物
PCT/CA1998/000841 WO1999012543A1 (en)	1997-09-05	1998-09-03	Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agents
AU90570/98A AU759990B2 (en)	1997-09-05	1998-09-03	Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agents
JP2000510440A JP2001515861A (ja)	1997-09-05	1998-09-03	抗腫瘍薬としてのジチオロピロロンおよびそれらの対応するモノオキサイドおよびジオキサイド
CN01131401A CN1360891A (zh)	1997-09-05	2001-09-06	用作抗肿瘤剂的二硫杂环戊烯并吡咯酮及其相应的一氧化物和二氧化物
HK02107990.3A HK1046373A1 (zh)	1997-09-05	2002-11-02	用作抗腫瘤劑的二硫雜環戊烯並吡咯酮及其相應的一氧化物和二氧化物

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002212237A CA2212237A1 (en)	1997-09-05	1997-09-05	Novel antineoplastic agents

Publications (1)

Publication Number	Publication Date
CA2212237A1 true CA2212237A1 (en)	1999-03-05

Family

ID=4161181

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002212237A Abandoned CA2212237A1 (en)	1997-09-05	1997-09-05	Novel antineoplastic agents

Country Status (7)

Country	Link
EP (1)	EP1009401A1 (zh)
JP (1)	JP2001515861A (zh)
CN (2)	CN1276723A (zh)
AU (1)	AU759990B2 (zh)
CA (1)	CA2212237A1 (zh)
HK (1)	HK1046373A1 (zh)
WO (1)	WO1999012543A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1238668A1 (en) *	2001-03-09	2002-09-11	Aventis Pharma Deutschland GmbH	Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
JP4530667B2 (ja) *	2002-03-26	2010-08-25	ウェリケムバイオテックインコーポレーテッド	治療活性を有する新規ジチオロピロロン（ｄｉｔｈｉｏｌｏｐｙｒｒｏｌｏｎｅｓ）
EP2076519B1 (en)	2006-09-29	2014-01-15	Celestial Pharmaceuticals (Shenzhen) LTD.	Novel dithiolopyrrolones and their therapeutical applications
CN101381371B (zh)	2007-09-05	2011-05-18	上海医药工业研究院	二硫杂环戊烯并吡咯酮类化合物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1214130A (en) *	1982-10-26	1986-11-18	Stuart H. Rhodes	Xenorhabdin antibiotics
DE19513040A1 (de) *	1995-03-29	1996-10-02	Schering Ag	Neue Borneolester, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2217957A1 (en) *	1995-04-11	1996-10-17	Genhui Chen	Xenorxides with antibacterial and antimycotic properties

1997
- 1997-09-05 CA CA002212237A patent/CA2212237A1/en not_active Abandoned
1998
- 1998-09-03 EP EP98942414A patent/EP1009401A1/en not_active Withdrawn
- 1998-09-03 WO PCT/CA1998/000841 patent/WO1999012543A1/en active IP Right Grant
- 1998-09-03 AU AU90570/98A patent/AU759990B2/en not_active Ceased
- 1998-09-03 JP JP2000510440A patent/JP2001515861A/ja active Pending
- 1998-09-03 CN CN98810328A patent/CN1276723A/zh active Pending
2001
- 2001-09-06 CN CN01131401A patent/CN1360891A/zh active Pending
2002
- 2002-11-02 HK HK02107990.3A patent/HK1046373A1/zh unknown

Also Published As

Publication number	Publication date
HK1046373A1 (zh)	2003-01-10
EP1009401A1 (en)	2000-06-21
CN1360891A (zh)	2002-07-31
WO1999012543A1 (en)	1999-03-18
JP2001515861A (ja)	2001-09-25
AU759990B2 (en)	2003-05-01
CN1276723A (zh)	2000-12-13
AU9057098A (en)	1999-03-29

Publication	Publication Date	Title
US5010099A (en)	1991-04-23	Discodermolide compounds, compositions containing same and method of preparation and use
US5583239A (en)	1996-12-10	Antimicrobial sterol conjugates
JP3008985B2 (ja)	2000-02-14	ジスコダーモライド化合物類、これらを含有する組成物類、及び製造及び使用法
OKAMOTO et al.	1986	Studies of platelet activating factor (PAF) antagonists from microbial products. I.: bisdethiobis (methylthio) gliotoxin and its derivatives
US4268676A (en)	1981-05-19	Mitomycin analogs
US7375129B2 (en)	2008-05-20	Bis-indole pyrroles useful as antimicrobials agents
HUP0204347A2 (en)	2003-05-28	Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them and their use
Sakai et al.	2005	Xanthocillins as thrombopoietin mimetic small molecules
AU759990B2 (en)	2003-05-01	Dithiolopyrrolones and their corresponding monoxides and dioxides as antineoplastic agents
US6583171B1 (en)	2003-06-24	Antineoplastic agents
US5827872A (en)	1998-10-27	Xenomins novel heterocyclic compounds with antimicrobial and antneoplastic properties
WO1999032115A1 (en)	1999-07-01	Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
US5298523A (en)	1994-03-29	Method for treating transplant patients using mycalamide compounds
LI et al.	0	Sommaire du brevet 2212237
Reddy et al.	2000	Chemical investigation of Mycale mytilorum and a study on toxicity and antidiabetic activity of 5-octadecylpyrrole-2-carboxaldehyde
LI et al.	0	Patent 2212237 Summary
US4460599A (en)	1984-07-17	Mitomycin analogs
KR960005150B1 (ko)	1996-04-22	신규한 nf-1616-904의 피라진옥사이드 화합물 및 이를 함유하는 약학 조성물
CA2217957A1 (en)	1996-10-17	Xenorxides with antibacterial and antimycotic properties
JPH10120563A (ja)	1998-05-12	免疫抑制剤
EP0108455B1 (en)	1987-04-22	Sparsomycin (sc-rs) derivative; pharmaceutical composition having anti-tumor activity
WO2019189331A1 (ja)	2019-10-03	新規ｋ９５－５９０１－１物質およびその製造方法
WO2007010307A1 (en)	2007-01-25	Antineoplastic compounds
JP2006503049A (ja)	2006-01-26	ソルビシルラクトンａおよびソルビシルラクトンａ誘導体、これらの製造方法、これらを含有する薬剤、およびこれらの使用
US5910509A (en)	1999-06-08	Antimicrobial agent for agriculture

Legal Events

Date	Code	Title	Description
1997-09-05	EEER	Examination request
2001-07-17	FZDE	Dead